Table 3.

Treatment-emergent AEs occurring in at least 2 patients regardless of attribution

	n (%)
	100 mg (n = 6)		150 mg (n = 6)		Total (N = 12)
	Grade 1/2	Grade 3	Grade 1/2	Grade 3	All grades
Diarrhea	5 (83.3)	1 (16.7)	5 (83.3)		11 (91.7)
Fatigue	4 (66.7)	2 (33.3)	3 (50.0)	1 (16.7)	10 (83.3)
Constipation	6 (100)		4 (66.7)		10 (83.3)
Nausea	5 (83.3)		5 (83.3)		10 (83.3)
Headache	4 (66.7)	1 (16.7)	2 (33.3)		7 (50)
Abdominal pain	4 (66.7)		2 (33.3)		6 (50)
Upper respiratory tract infection	1 (16.7)		4 (66.7)		5 (41.7)
Dry skin	2 (33.3)		2 (33.3)		4 (33.3)
Pain	2 (33.3)	1 (16.7)	1 (16.7)		4 (33.3)
Pruritus	2 (33.3)		2 (33.3)		4 (33.3)
Vomiting	3 (50.0)		1 (16.7)		4 (33.3)
Arthralgia	3 (50)				3 (25)
Dizziness	3 (50)				3 (25)
Cough	2 (33.3)		1 (16.7)		3 (25.0)
Decreased appetite	2 (33.3)		1 (16.7)		3 (25.0)
Dyspepsia	2 (33.3)		1 (16.7)		3 (25.0)
Flushing	2 (33.3)		1 (16.7)		3 (25.0)
Oropharyngeal pain	1 (16.7)		2 (33.3)		3 (25.0)
Dysgeusia	1 (16.7)		2 (33.3)		3 (25.0)
Dyspepsia	2 (33.3)		1 (16.7)		3 (25.0)
Epistaxis	1 (16.7)		1 (16.7)		2 (16.7)
Weight gain	1 (16.7)		1 (16.7)		2 (16.7)
Alopecia	1 (16.7)		1 (16.7)		2 (16.7)
Anorexia	1 (16.7)		1 (16.7)		2 (16.7)
Back pain	1 (16.7)		1 (16.7)		2 (16.7)
Chest pain	2 (33.3)				2 (16.7)
Disorientation	2 (33.3)				2 (16.7)
Eye infection	1 (16.7)		1 (16.7)		2 (16.7)
Flatulence	1 (16.7)		1 (16.7)		2 (16.7)
GERD	1 (16.7)		1 (16.7)		2 (16.7)
Heartburn	1 (16.7)		1 (16.7)		2 (16.7)
Rash			2 (33.3)		2 (16.7)
Sinusitis	2 (16.7)				2 (16.7)

GERD, gastroesophageal reflux disease.